CIK: 0001595725
Total reported value
$1.7B
Reporting period: 2026-03-31 · Number of holdings: 100
Rock Springs Capital Management LP disclosed 100 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.7B and a quarterly turnover rate of 35.5%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "R"
Rock Springs Capital Management LP's disclosed holdings carry a Herfindahl concentration index of 0.026 — mathematically equivalent to about 39 equally-sized positions, well below its 100 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.26), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 44% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim TVTX
-33.1% -$40.5M
Add RVMD
-9.4% $11.3M
Trim AM6
-98.9% -$27.2M
Add MIRM
+6.4% $14.7M
Add ELVN
+3.5% $20.1M
Trim XBI
-86.5% -$23.2M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines INC | Stock-Healthcare | 6.93% | +1.48% | -9.42% | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 5.35% | -0.46% | -6.36% | |
| 3 | MDGL | Madrigal Pharmaceuticals INC | Stock-Healthcare | 5.28% | +1.11% | +22.48% | |
| 4 | MIRM | Mirum Pharmaceuticals INC | Stock-Other | 4.42% | +1.33% | +6.43% | |
| 5 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.24% | -0.21% | -4.60% | |
| 6 | RYTM | Rhythm Pharmaceuticals INC | Stock-Other | 3.54% | -0.27% | -0.76% | |
| 7 | INSM | Insmed INC | Stock-Healthcare | 3.03% | +0.18% | -1.55% | |
| 8 | ASND | Ascendis Pharma A/S | Stock-Other | 2.62% | — | -4.67% | |
| 9 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 2.62% | +0.81% | -3.14% | |
| 10 | TVTX | Travere Therapeutics INC | Stock-Other | 2.59% | -1.74% | -33.13% | |
| 11 | KYMR | Kymera Therapeutics INC | Stock-Other | 2.44% | — | — | |
| 12 | PEN | Penumbra INC | Stock-Healthcare | 2.33% | — | — | |
| 13 | ISRG | Intuitive Surgical INC | Stock-Healthcare | 2.23% | -0.15% | — | |
| 14 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.14% | +0.48% | +0.86% | |
| 15 | ELVN | Enliven Therapeutics INC | Stock-Other | 1.91% | +1.28% | +3.52% | |
| 16 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.91% | -0.04% | +29.13% | |
| 17 | IRTC | Irhythm Holdings INC | Stock-Healthcare | 1.82% | -0.32% | +11.38% | |
| 18 | GPCR | Structure Therapeutics INC | Stock-Other | 1.82% | -0.85% | -14.44% | |
| 19 | AGIO | Agios Pharmaceuticals INC | Stock-Other | 1.59% | +0.47% | — | |
| 20 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.50% | +0.01% | -3.82% | |
| 21 | ALNY | Alnylam Pharmaceuticals INC | Stock-Healthcare | 1.44% | -0.01% | +3.86% | |
| 22 | COGT | Cogent Biosciences INC | Stock-Other | 1.42% | -0.13% | -26.49% | |
| 23 | THC | Tenet Healthcare CORP | Stock-Healthcare | 1.39% | — | — | |
| 24 | DXCM | Dexcom INC | Stock-Healthcare | 1.32% | — | +2.39% | |
| 25 | CLDX | Celldex Therapeutics INC | Stock-Other | 1.22% | — | -6.10% | |
| 26 | VERA | Vera Therapeutics INC | Stock-Other | 1.19% | -0.29% | -11.43% | |
| 27 | NBIX | Neurocrine Biosciences INC | Stock-Healthcare | 1.17% | — | +19.88% | |
| 28 | ACLXGBX | Arcellx INC | Stock-Other | 1.15% | +0.58% | — | |
| 29 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.11% | — | — | |
| 30 | PHVS | Pharvaris N.V. | Stock-Other | 1.07% | — | +3.55% | |
| 31 | ERAS | Erasca INC | Stock-Other | 1.05% | +0.87% | +15.95% | |
| 32 | DYN | Dyne Therapeutics INC | Stock-Other | 1.04% | — | +6.49% | |
| 33 | CMPX | Compass Therapeutics INC | Stock-Other | 1.03% | — | -15.84% | |
| 34 | ACRS | Aclaris Therapeutics INC | Stock-Other | 0.99% | — | +0.42% | |
| 35 | TARS | Tarsus Pharmaceuticals INC | Stock-Other | 0.93% | -0.16% | -13.51% | |
| 36 | MMED | Minimed Group INC | Stock-Other | 0.93% | +0.93% | NEW | |
| 37 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 0.90% | — | +0.39% | |
| 38 | UNH | Unitedhealth Group INC | Stock-Healthcare | 0.85% | — | +29.90% | |
| 39 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.82% | +0.40% | +8.58% | |
| 40 | HTFL | Heartflow INC | Stock-Other | 0.82% | +0.40% | +106.16% | |
| 41 | ARDX | Ardelyx INC | Stock-Other | 0.81% | — | — | |
| 42 | SMMT | Summit Therapeutics INC | Stock-Other | 0.79% | — | — | |
| 43 | AZTA | Azenta INC | Stock-Other | 0.71% | -0.26% | — | |
| 44 | MLYS | Mineralys Therapeutics INC | Stock-Other | 0.70% | -0.10% | +2.84% | |
| 45 | DHR | Danaher CORP | Stock-Healthcare | 0.69% | — | — | |
| 46 | PTCT | Ptc Therapeutics INC | Stock-Healthcare | 0.65% | +0.41% | +161.47% | |
| 47 | CAI | Caris Life Sciences INC | Stock-Other | 0.59% | -0.36% | -18.11% | |
| 48 | ZBIO | Zenas Biopharma INC | Stock-Other | 0.58% | -0.35% | — | |
| 49 | BCAX | Bicara Therapeutics INC | Stock-Other | 0.57% | — | +13.98% | |
| 50 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 0.56% | — | +23.91% |
Performance for Q3 2026
+46.3%
Performance Last 4 Quarters
+78%
Based on 79% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 100 | $1.7B | 35 | |
| 2025-12-31 | 99 | $2.0B | 37 | |
| 2025-09-30 | 93 | $1.7B | 56 | |
| 2025-06-30 | 93 | $1.6B | 0 | |
| 2025-03-31 | 96 | $1.7B | 100 | |
| 2024-12-31 | 107 | $2.6B | 0 | |
| 2024-09-30 | 109 | $3.1B | 0 | |
| 2024-06-30 | 112 | $3.3B | 0 | |
| 2024-03-31 | 114 | $3.9B | 0 | |
| 2023-12-31 | 104 | $4.1B | 0 | |
| 2023-09-30 | 120 | $3.7B | 0 | |
| 2023-06-30 | 123 | $4.2B | 0 | |
| 2023-03-31 | 121 | $4.2B | 0 | |
| 2022-12-31 | 120 | $4.2B | 0 | |
| 2022-09-30 | 128 | $3.9B | 0 | |
| 2022-06-30 | 131 | $3.4B | 0 | |
| 2022-03-31 | 135 | $4.0B | 0 | |
| 2021-12-31 | 136 | $4.3B | 0 | |
| 2021-09-30 | 153 | $4.8B | 0 | |
| 2021-06-30 | 156 | $5.1B | 33 | |
| 2021-03-31 | 151 | $4.6B | 42 | |
| 2020-12-31 | 155 | $4.7B | 41 | |
| 2020-09-30 | 148 | $3.9B | 37 | |
| 2020-06-30 | 143 | $3.6B | 45 | |
| 2020-03-31 | 131 | $2.4B | 51 | |
| 2019-12-31 | 130 | $3.2B | 49 | |
| 2019-09-30 | 138 | $2.5B | 32 | |
| 2019-06-30 | 135 | $2.8B | 23 | |
| 2019-03-31 | 131 | $2.6B | 36 | |
| 2018-12-31 | 133 | $2.1B | 35 | |
| 2018-09-30 | 144 | $2.8B | 32 | |
| 2018-06-30 | 147 | $2.6B | 31 | |
| 2018-03-31 | 149 | $2.3B | 46 | |
| 2017-12-31 | 145 | $2.2B | 31 | |
| 2017-09-30 | 147 | $2.2B | 30 | |
| 2017-06-30 | 149 | $2.0B | 40 | |
| 2017-03-31 | 140 | $1.7B | 26 | |
| 2016-12-31 | 133 | $1.5B | 31 | |
| 2016-09-30 | 137 | $1.6B | 36 | |
| 2016-06-30 | 137 | $1.4B | 32 | |
| 2016-03-31 | 128 | $1.2B | 27 | |
| 2015-12-31 | 120 | $1.3B | 50 | |
| 2015-09-30 | 121 | $1.2B | 46 | |
| 2015-06-30 | 117 | $1.4B | 48 | |
| 2015-03-31 | 105 | $1.1B | 67 | |
| 2014-12-31 | 93 | $854.9M | 52 | |
| 2014-09-30 | 83 | $646.4M | 40 | |
| 2014-06-30 | 78 | $557.7M | 63 | |
| 2014-03-31 | 75 | $433.6M | 65 | |
| 2013-12-31 | 69 | $279.9M | 0 |
Rock Springs Capital Management LP's most significant position changes for 2026-03-31: Sold out: Exact Sciences CORP (EXK); Sold out: Cidara Therapeutics INC (CDTX); New buy: Minimed Group INC (MMED); Sold out: Rapt Therapeutics INC (RAPT); Sold out: Gossamer Bio INC (GOSS 5 06-01-27).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines INC | +1.5% | -9.42% | Trim |
| 2 | MIRM | Mirum Pharmaceuticals INC | +1.3% | +6.43% | Add |
| 3 | ELVN | Enliven Therapeutics INC | +1.3% | +3.52% | Add |
| 4 | MDGL | Madrigal Pharmaceuticals INC | +1.1% | +22.48% | Add |
| 5 | ERAS | Erasca INC | +0.9% | +15.95% | Add |
| 6 | XENE | Xenon Pharmaceuticals INC | +0.8% | -3.14% | Trim |
| 7 | ACLXGBX | Arcellx INC | +0.6% | — | Unchanged |
| 8 | SRRK | Scholar Rock Holding CORP | +0.5% | +0.86% | Add |
| 9 | AGIO | Agios Pharmaceuticals INC | +0.5% | — | Unchanged |
| 10 | PTCT | Ptc Therapeutics INC | +0.4% | +161.47% | Add |
| 11 | 260 | Centessa Pharmaceuticals-adr | +0.4% | +8.58% | Add |
| 12 | HTFL | Heartflow INC | +0.4% | +106.16% | Add |
| 13 | TNGX | Tango Therapeutics INC | +0.3% | — | Unchanged |
| 14 | INSM | Insmed INC | +0.2% | -1.55% | Trim |
| 15 | RARE | Ultragenyx Pharmaceutical In | 0% | -3.82% | Trim |
| 16 | ALNY | Alnylam Pharmaceuticals INC | 0% | +3.86% | Add |
| 17 | BSX | Boston Scientific CORP | 0% | +29.13% | Add |
| 18 | MLYS | Mineralys Therapeutics INC | -0.1% | +2.84% | Add |
| 19 | COGT | Cogent Biosciences INC | -0.1% | -26.49% | Trim |
| 20 | ISRG | Intuitive Surgical INC | -0.2% | — | Unchanged |
| 21 | TARS | Tarsus Pharmaceuticals INC | -0.2% | -13.51% | Trim |
| 22 | EVH | Evolent Health INC - A | -0.2% | — | Unchanged |
| 23 | OMDA | Omada Health INC | -0.2% | -26.89% | Trim |
| 24 | ARGX | Argenx Se - Adr | -0.2% | -4.60% | Trim |
| 25 | INSP | Inspire Medical Systems INC | -0.2% | +0.61% | Add |
| 26 | EW | Edwards Lifesciences CORP | -0.2% | -64.97% | Trim |
| 27 | AZTA | Azenta INC | -0.3% | — | Unchanged |
| 28 | RYTM | Rhythm Pharmaceuticals INC | -0.3% | -0.76% | Trim |
| 29 | VERA | Vera Therapeutics INC | -0.3% | -11.43% | Trim |
| 30 | IRTC | Irhythm Holdings INC | -0.3% | +11.38% | Add |
| 31 | ZBIO | Zenas Biopharma INC | -0.4% | — | Unchanged |
| 32 | CAI | Caris Life Sciences INC | -0.4% | -18.11% | Trim |
| 33 | LLY | Eli Lilly & Co | -0.5% | -6.36% | Trim |
| 34 | PHR | Phreesia INC | -0.5% | -31.51% | Trim |
| 35 | GOSS | Gossamer Bio INC | -0.5% | -50.73% | Trim |
| 36 | GPCR | Structure Therapeutics INC | -0.9% | -14.44% | Trim |
| 37 | XBI | Ss Spdr S&p Biotech ETF | -1.2% | -86.49% | Trim |
| 38 | AM6 | Amicus Therapeutics INC | -1.4% | -98.91% | Trim |
| 39 | TVTX | Travere Therapeutics INC | -1.7% | -33.13% | Trim |
| 40 | EXK | Exact Sciences CORP | — | EXIT | Sold out |
| 41 | CDTX | Cidara Therapeutics INC | — | EXIT | Sold out |
| 42 | MMED | Minimed Group INC | — | NEW | New buy |
| 43 | RAPT | Rapt Therapeutics INC | — | EXIT | Sold out |
| 44 | GOSS 5 06-01-27 | Gossamer Bio INC | — | EXIT | Sold out |
| 45 | INDV | Indivior Pharmaceuticals INC | — | NEW | New buy |
| 46 | SYK | Stryker CORP | — | NEW | New buy |
| 47 | AGL | agilon health, inc. | — | EXIT | Sold out |
| 48 | MRSN | Mersana Therapeutics INC | — | EXIT | Sold out |
| 49 | TBPH | Theravance Biopharma, Inc. | — | EXIT | Sold out |
| 50 | INDV | Indivior Pharmaceuticals, Inc. | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-14 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-15 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-14 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-14 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-15 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-16 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-16 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-11-16 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-08-14 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-05-15 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-02-17 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-05-15 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001396835
Total reported value
$1.7B
70 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001697953
Total reported value
$1.7B
483 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001940272
Total reported value
$1.7B
311 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001493215
Total reported value
$10.0B
88 stks
2026-03-31
2 of the top 5 holdings overlap, including Madrigal Pharmaceuticals INC
CIK 0001633313
Total reported value
$10.2B
33 stks
2026-03-31
2 of the top 5 holdings overlap, including Madrigal Pharmaceuticals INC
CIK 0001937964
Total reported value
$499.4M
50 stks
2026-03-31
2 of the top 5 holdings overlap, including Eli Lilly & Co